NICE’s decision will allow access to an innovative treatment channel which will help to address an unmet need for eligible people in England and Wales with CML who typically develop intolerance or resistance to current treatment with tyrosine kinase inhibitors (TKIs).
The decision makes Scemblix the first treatment in its class to be authorised in Britain.
The approval for recommendation of Scemblix – a specifically targeting the abl myristoyl pocket (STAMP) inhibitor – is for Ph+ CML patients in CP who have received previous treatment using two or more tyrosine kinase inhibitors, without a known T315I mutation…
